Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined orphan neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s and Parkinson’s disorders.
Just as cancer is composed of many different subtypes, we believe dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, we are developing breakthrough biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are genetically-defined.
To deliver our first-in-class disease-modifying therapies, we are employing our proprietary, implantable bioreactor device with cells engineered to manufacture single or multiple therapeutic factors locally within the brain.
Our web site is under construction. Please contact us to learn more about what we are doing to develop novel therapies for familial dementia and other neurodegenerative disorders.
